Zhitong Finance App News, Keji Pharmaceutical-B (02171.HK) issued an announcement. A summary of research results on CT1190B (a generic CAR-T candidate product targeting CD19/CD20) for the treatment of relapsed/refractory large B-cell lymphoma, and CT071 (an autologous CAR-T candidate product targeting GPRC5D) to treat relapsed/refractory multiple myeloma (R/R MM) and high-risk newly diagnosed multiple myeloma (HR-NDMM) were summarized at the 68th American Hematology Conference (ASH) Annual Meeting Published. Research data for the two candidate products will be presented in the form of posters at the ASH annual conference. Research updates on CT0596 (a generic CAR-T candidate product targeting BCMA) for the treatment of R/R MM and primary plasma cell leukemia will be published in a separate company announcement in December 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.